litlas
ログインアカウント作成

Anna C. Pavlick

2005–2025 年に発表

別表記
Anna C Pavlick
89
論文数
21,032
被引用数
65
h 指数
89
i10 指数

被引用数

Anna C. Pavlick の年別被引用数2001 年: 被引用 1 件2006 年: 被引用 2 件2007 年: 被引用 15 件2008 年: 被引用 42 件2009 年: 被引用 50 件2010 年: 被引用 67 件2011 年: 被引用 91 件2012 年: 被引用 189 件2013 年: 被引用 274 件2014 年: 被引用 299 件2015 年: 被引用 353 件2016 年: 被引用 413 件2017 年: 被引用 473 件2018 年: 被引用 426 件2019 年: 被引用 1,035 件2020 年: 被引用 1,061 件2021 年: 被引用 920 件2022 年: 被引用 815 件2023 年: 被引用 603 件2024 年: 被引用 790 件2025 年: 被引用 379 件2026 年: 被引用 2 件2002〜2005 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,358 件、この内訳の 29.6%中国: 引用元論文 1,103 件、この内訳の 9.7%ドイツ: 引用元論文 654 件、この内訳の 5.8%イタリア: 引用元論文 638 件、この内訳の 5.6%イギリス: 引用元論文 556 件、この内訳の 4.9%フランス: 引用元論文 549 件、この内訳の 4.8%オーストラリア: 引用元論文 498 件、この内訳の 4.4%スペイン: 引用元論文 357 件、この内訳の 3.1%オランダ: 引用元論文 338 件、この内訳の 3%カナダ: 引用元論文 327 件、この内訳の 2.9%スイス: 引用元論文 305 件、この内訳の 2.7%日本: 引用元論文 261 件、この内訳の 2.3%
0%29.6%その他 21.2%

機関

分野

  • Medicine58.6%
  • Biochemistry, Genetics and Molecular Biology28.6%
  • Immunology and Microbiology9.5%
  • Computer Science0.8%
  • Engineering0.7%
  • Neuroscience0.5%
  • その他1.3%

トピック

  • Cancer Immunotherapy and Biomarkers14.5%
  • Immunotherapy and Immune Responses7.4%
  • Melanoma and MAPK Pathways7.1%
  • CAR-T cell therapy research6.1%
  • Cutaneous Melanoma Detection and Management4.8%
  • Immune Cell Function and Interaction3%
  • その他57.1%

共著者

全論文

検索で開く
  1. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

    著者: Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Karl D. Lewis, Theresa Medina, Harriet M. Kluger, Sajeve Thomas, Evidio Domingo‐Musibay, Anna C. Pavlick, Eric D. Whitman, Salvador Martín‐Algarra, Pippa Corrie, Brendan D. Curti, Judit Oláh, Jose Lutzky, Jeffrey S. Weber, James Larkin, Wen Shi, Toshimi Takamura, Madan Jagasia, Harry Qin, Xiao Wu, Cécile Chartier, Friedrich Graf Finckenstein, Maria Fardis, John M. Kirkwood, Jason Chesney - Journal of Clinical Oncology 2021 被引用: 410

  2. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

    著者: Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi - New England Journal of Medicine 2015 被引用: 2,763

  3. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    著者: Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Anna C. Pavlick, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Margolin - New England Journal of Medicine 2018 被引用: 1,321

  4. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

    著者: Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, Alain P Algazi, Omid Hamid, Christopher D Lao, Stergios J Moschos, Michael B Atkins, Karl Lewis, Michael A Postow, Reena P Thomas, John Glaspy, Sekwon Jang, Nikhil I Khushalani, Anna C Pavlick, Marc S Ernstoff, David A Reardon, Ragini Kudchadkar, Ahmad Tarhini, Caroline Chung, Corey Ritchings, Piyush Durani, Margarita Askelson, Igor Puzanov, Kim A Margolin - The Lancet Oncology 2021 被引用: 322

  5. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

    著者: Scott J. Rodig, Daniel Gusenleitner, Donald Jackson, Evisa Gjini, Anita Giobbie‐Hurder, Chelsea Jin, Han Chang, Scott B. Lovitch, Christine E. Horak, Jeffrey S. Weber, Jason L. Weirather, Jedd D. Wolchok, Michael A. Postow, Anna C. Pavlick, Jason Chesney, F. Stephen Hodi - Science Translational Medicine 2018 被引用: 584

  6. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    著者: Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Carmen Loquai, Thomas Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira‐Frommer, René González, John M. Kirkwood, Jedd D. Wolchok, Alexander M.M. Eggermont, Xiaoyun Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, Sunyu Kang, Adil Daud - The Lancet Oncology 2015 被引用: 1,564

  7. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    著者: F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Christine E. Horak, Paul Gagnier, Joel Jiang, Jedd D. Wolchok, Michael A. Postow - The Lancet Oncology 2016 被引用: 980

  8. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

    著者: Brandilyn A. Peters, Melissa Wilson, Una Moran, Anna C. Pavlick, Allison Izsak, Todd Wechter, Jeffrey S. Weber, Iman Osman, Jiyoung Ahn - Genome Medicine 2019 被引用: 278

  9. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

    著者: Paul Johannet, Nicolas Coudray, Douglas M. Donnelly, George Jour, Irineu Illa-Bochaca, Yuhe Xia, Douglas B. Johnson, Lee Wheless, James R. Patrinely, Sofia Nomikou, David L. Rimm, Anna C. Pavlick, Jeffrey S. Weber, Judy Zhong, Aristotelis Tsirigos, Iman Osman - Clinical Cancer Research 2020 被引用: 183

  10. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    著者: Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, René González, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald P. Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, K. B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas - New England Journal of Medicine 2012 被引用: 2,148

  11. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    著者: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 被引用: 933

  12. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

    著者: Danny Rischin, Michael R. Migden, Annette M. Lim, Chrysalyne D. Schmults, Nikhil I. Khushalani, Brett Hughes, Dirk Schadendorf, Lara Dunn, Leonel F. Hernandez‐Aya, Anne Lynn S. Chang, Badri Modi, Axel Hauschild, Claas Ulrich, Thomas Eigentler, B. Stein, Anna C. Pavlick, J.L. Geiger, Ralf Gutzmer, Murad Alam, Emmanuel Chiebuka Okoye, Melissa Mathias, Vladimir Janković, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, Israel Lowy, Matthew G. Fury, Alexander Guminski - Journal for ImmunoTherapy of Cancer 2020 被引用: 175

  13. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival

    著者: Dusan Bogunovic, David O’Neill, Ilana Belitskaya‐Lévy, Vladimir Vacic, Yi-Lo Yu, Sylvia Adams, Farbod Darvishian, Russell S. Berman, Richard L. Shapiro, Anna C. Pavlick, Stefano Lonardi, Jiří Zavadil, Iman Osman, Nina Bhardwaj - National Academy of Sciences, Proceedings of the National Academy of Sciences 2009 被引用: 381

  14. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

    著者: Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick, Raoul Tibes, Lee Rosen, Albiruni Ryan Abdul Razak, Raymond W. Lam, Tim Demuth, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, Stuart D. Shumway, Li Liang, Amit M. Oza, Jan H.M. Schellens, Geoffrey I. Shapiro - Journal of Clinical Oncology 2016 被引用: 269

  15. The State of Melanoma: Emergent Challenges and Opportunities

    著者: Michael B. Atkins, Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso, Marı́a S. Soengas, Ashani T. Weeraratna, Keith T. Flaherty, Meenhard Herlyn, Jeffrey A. Sosman, Hussein A. Tawbi, Anna C. Pavlick, Pamela B. Cassidy, Sunandana Chandra, Paul B. Chapman, Adil Daud, Zeynep Eroglu, Laura K. Ferris, Bernard A. Fox, Jeffrey E. Gershenwald, Geoffrey T. Gibney, Douglas Grossman, Brent A. Hanks, Douglas Hanniford, Eva Hernando, Joanne Jeter, Douglas B. Johnson, Samir N. Khleif, John M. Kirkwood, Sancy A. Leachman, Darren Mays, Kelly C. Nelson, Vernon K. Sondak, Ryan J. Sullivan, Glenn Merlino - Clinical Cancer Research 2021 被引用: 108

  16. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

    著者: Drew Rasco, Theresa Medina, Pippa Corrie, Anna C. Pavlick, Mark R. Middleton, Paul Lorigan, Chris J. Hebert, Ruth Plummer, James Larkin, Sanjiv S. Agarwala, Adil Daud, Jiaheng Qiu, Viviana Bozón, Michelle Kneissl, Elly Barry, Anthony J. Olszanski - Cancer Chemotherapy and Pharmacology 2023 被引用: 40

  17. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

    著者: Nina Bhardwaj, Philip Friedlander, Anna C. Pavlick, Marc S. Ernstoff, Brian Gastman, Brent A. Hanks, Brendan D. Curti, Mark R. Albertini, Jason J. Luke, Ana-Belén Blázquez, Sreekumar Balan, Davide Bedognetti, Joseph Beechem, Andrea Crocker, Leonard D’Amico, Patrick Danaher, Thomas A. Davis, Thomas Hawthorne, Bruce W. Hess, Tibor Keler, Lisa Lundgren, Chihiro Morishima, Nirasha Ramchurren, Darawan Rinchai, Andres Μ. Salazar, Bob Salim, Elad Sharon, Laura Vitale, Ena Wang, Sarah Warren, Michael Yellin, Mary L. Disis, Martin A. Cheever, Steven P. Fling - Nature Cancer 2020 被引用: 126

  18. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma

    著者: Mykhaylo Usyk, Abhishek Pandey, Richard B. Hayes, Una Moran, Anna C. Pavlick, Iman Osman, Jeffrey S. Weber, Jiyoung Ahn - Genome Medicine 2021 被引用: 70

  19. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

    著者: Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Thomas, John A. Glaspy, Sekwon Jang, Alain P. Algazi, Nikhil I. Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Ahmad A. Tarhini, Anne Sumbul, Jasmine I. Rizzo, Kim Margolin - Neuro-Oncology 2021 被引用: 125

  20. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

    著者: Anna C. Pavlick, Ana-Belén Blázquez, Marcia Meseck, Michael Lattanzi, Patrick A. Ott, Thomas U. Marron, Rose Marie Holman, John Mandeli, Andres Μ. Salazar, Christopher B. McClain, Gustavo Giménez, Sreekumar Balan, Sacha Gnjatic, Rachel Lubong Sabado, Nina Bhardwaj - Cancer Immunology Research 2019 被引用: 73

  21. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    著者: Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis - Journal of Clinical Oncology 2012 被引用: 477

  22. A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma

    著者: Ahmad A. Tarhini, Michael Millward, Paul N. Mainwaring, Richard Kefford, T. Logan, Anna C. Pavlick, Steven J. Kathman, Kevin Laubscher, Mohammed M. Dar, John M. Kirkwood - Cancer 2009 被引用: 121

  23. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

    著者: Omid Hamid, Igor Puzanov, Reinhard Dummer, Jacob Schachter, Adil Daud, Dirk Schadendorf, Christian U. Blank, Lee D. Cranmer, Caroline Robert, Anna C. Pavlick, René González, F. Stephen Hodi, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Tara C. Gangadhar, Ziwen Wei, Scot Ebbinghaus, Nageatte Ibrahim, Antoni Ribas - European Journal of Cancer 2017 被引用: 180

  24. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

    著者: Shailender Bhatia, Anna C. Pavlick, Peter D. Boasberg, John A. Thompson, George Mulligan, Michael D. Pickard, Hélène M. Faessel, Bruce J. Dezube, Omid Hamid - Investigational New Drugs 2016 被引用: 112